Pictilisib (GDC-0941)

製品コードS1065 別名:RG7321

Pictilisib (GDC-0941)化学構造

分子量(MW):513.64

Pictilisib (GDC-0941)は1種の有効なPI3Kα/δ阻害剤です。無細胞試験で、Pictilisib (GDC-0941)はPI3Kα/δに作用する時の IC50値は 3 nM で、p110β (11倍) とp110γ (25倍)に適合な選択性をしています。臨床2期。

サイズ 価格 在庫  
USD 302 あり
USD 151 あり
USD 214 あり
USD 466 あり
USD 1222 あり

文献中の引用(58)

カスタマーフィードバック(8)

  • Dual PI3K/BRAF inhibition upregulates BIM and enhances apoptosis in PTEN cells. A, left, Western blot of 1205Lu cells treated with PLX4720 (3 μmol/L, 48 hours), the PI3K inhibitor GDC-0941 (3 μmol/L, 48 hours), or both drugs in combination (PtG); right, immunofluorescence staining of BIM (green) and DAPI (blue) in PTEN cells following PLX4720 treatment (3 μmol/L, 48 hours), the PI3K inhibitor LY294002 (10 μmol/L, 48 hours), or both drugs in combination (PLXtLY). B, left, immunofluorescence staining of PTEN 1205Lu following combined inhibition (3 μmol/L PLX4720 t 10 μmol/L LY294002, 48hours) increases nuclear localization of FOXO3a (green). DAPI is shown in blue. Magnification 40. Right, combined inhibition (3 μmol/L PLX4720 t 10 μmol/L LY294002, 48 hours) increases PTEN WM793 BIM mRNA levels to those observed with single BRAF inhibition (3 μmol/L PLX4720, 48 hours) in the PTENt WM35. C, PTEN cells were treated with PLX4720 (3 μmol/L, 48 hours), GDC-0941 (3 μmol/L, 48hours), or a combination of the 2 drugs (3Pt3G) before Annexin-V staining was analyzed by flow cytometry (*, P < 0.05 between the drug combination and each inhibitor alone). D, combined BRAF/PI3K inhibitor treatment blocks the escape of 1205Lu cells (PTEN) from therapy. Spheroids of 1205Lu cells were treated with either PLX4720 alone (3 and 10 μmol/L: data shows 3 mmol/L), LY294002 (10 μmol/L) alone or a combination of the 2 drugs for 72 hours. In other studies, spheroids were treated with drugs for 72 hours and then allowed to recover for 120 hours. Micrograph shows viability staining (green= live cells, red= dead cells). Magnification 10×.

    Cancer Res 2011 71, 2750-2760. Pictilisib (GDC-0941) purchased from Selleck.

    Combination of rapamycin and PI-103 leads to the suppression of AKT phosphorylation (phospho-specific western blot). Mel-Juso and 518A2 cells were treated with GDC-0941 from 0.05–1 μmol/L alone and in combination with rapamycin (50 nmol/L) for 24 hours. Control treatment was with DMSO.

     

     

    J Inves Der 2010 131, 495-503. Pictilisib (GDC-0941) purchased from Selleck.

  • Growth inhibition induced by the FGFR inhibitor BGJ398 and the PI3K inhibitors alone or in combination. AN3CA (A-C), JHUEM2 (D-F) and MFE296 (G-I) cells were treated with the indicated doses of BGJ398, GDC-0941 a n d BYL719 alone or in combination for 96 hours and an Sulforhodamine B (SRB) assay was subsequently performed. Data are presented as a percentage of the control, in which cells were treated with 0.1% (v/v) DMSO. Points represent the mean of three independent experiments (each performed in triplicate). Error bars represent the standard error of the mean (SEM) and lines were fitted using non-linear regression analysis. Interaction of BGJ398 and GDC-0941(redcircles) or BYL719(blacksquares) in AN3CA(C), JHUEM2(F) and MFE296(I). Median effect analysis was used to evaluate the interaction between the inhibitor combinations. Horizontal dotted lines indicate the boundaries for each interaction classification.

    Mol Cancer Ther, 2017.. Pictilisib (GDC-0941) purchased from Selleck.

    TGF-β induces mTORC2 activation. ( A ) NMuMG cells were treated with TGF-β for the indicated times before lysis and immunoblotting. (B ) NMuMG cells were treated or not with TGF-β for the indicated times, in the presence or absence of SB431542 or LY294002. Cell lysates were subjected to anti-Rictor immunoprecipitation, and the immunoprecipitates were subjected to in vitro kinase assays using kinase-inactive Akt1 as a substrate, before immunoblotting of the kinase reactions, immunoprecipitates and cell lysates. The left panels are from the same gel, without differential exposure. ( C ) NMuMG cells were treated or not with TGF-β or insulin for the indicated times, in the presence or absence of SB431542 or GDC-0941. The kinase activity of mTORC2 was then assessed as in B. The top panels are from the same gel, without differential exposure. (D) NMuMG cells were treated or not with TGF-β for the indicated times, in the presence or absence of SB431542 or LY294002. Cell lysates were subjected to immunoprecipitation using Rictor antibody, and/or immunoblotted.

    J Cell Sci 2012 125(Pt 5), 1259-73. Pictilisib (GDC-0941) purchased from Selleck.

  • After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of GDC-0941  for 3h,followed by 15-minute  stimulation of 100ng/ml EGF.

     

     

     

    Dr. Zhang of Tianjin Medical University. Pictilisib (GDC-0941) purchased from Selleck.

    We treated all of drugs in T47D which has a PI3KCA H1044R mutation with the concentration shown below for 1 hour and performed western blot analysis using antibodies to phospho-AKT(SERINE 472), and total AKT.

     

     

    Saraswati Sukumar of Johns Hopkins University School of Medicine. Pictilisib (GDC-0941) purchased from Selleck.

  • Effects of LY294002 and GDC-0941 on the high-glucose-induced plasma membrane translocation of DGK δ1. (A, C) HEK293 cells were transfected with pAcGFP-DGKδ1 or pAcGFP-C1 vector. After being glucose-starved for 2.5 h and the subsequent pretreatment with (A) 10 μM LY294002 (Sigma-Aldrich) or (C) 1 μM GDC-0941 (Selleck Chemicals) for 30 min, the cells were incubated with or without high glucose (25 mM) for 5 min. The cells were fixed with 3.7% formaldehyde and observed using confocal laser-scanning microscopy. Scale bar = 10 μm. (B, D) After treatment with (B) LY294002 or (D) GDC-0941, the percentages of cells exhibiting the translocation of AcGFP-tagged DGK δ 1 to the plasma membrane were scored. More than 20 cells ex-pressing AcGFP-tagged DGK δ1 were counted in each experiment. The results are the means ± S.D. of three independent experiments. The statistical significance was deter-mined using Student's t -test (** P < 0.01, *** P < 0.005)

    Biochim Biophys Acta 2012 1823, 2210-6. Pictilisib (GDC-0941) purchased from Selleck.

     

    PI3K pathway signaling in GDC-0941 and MK-2206 treated MCF-7 derivatives with PIK3CA or  AKT1 mutations. Cells were grown in medium containing 5% FBS and treated with vehicle or increasing concentrations of GDC-0941 (0 nM, 50 nM, 100 nM, and 400 nM) or MK-2206 (0 nM, 100 nM, 250 nM, 1000 nM). After 24 hours of drug treatment, lysates were prepared and equal amounts of protein were load ed onto SDS-PAGE gels and blotted with the indicated antibodies.

    Pictilisib (GDC-0941) purchased from Selleck.

製品安全説明書

PI3K阻害剤の選択性比較

生物活性

製品説明 Pictilisib (GDC-0941)は1種の有効なPI3Kα/δ阻害剤です。無細胞試験で、Pictilisib (GDC-0941)はPI3Kα/δに作用する時の IC50値は 3 nM で、p110β (11倍) とp110γ (25倍)に適合な選択性をしています。臨床2期。
ターゲット
p110α [1]
(Cell-free assay)
p110δ [1]
(Cell-free assay)
p110β [1]
(Cell-free assay)
p110γ [1]
(Cell-free assay)
mTOR [1]
(Cell-free assay)
3 nM 3 nM 33 nM 75 nM 0.58 μM(Ki app)
体外試験

GDC-0941 is equipotent against PI3Kα and PI3Kδ as well as PI3Kα mutants E545-K and H1047-R, displaying modest levels of selectivity against PI3Kβ (10-fold) and PI3Kγ (25-fold), and greater levels of selectivity against members of PI3K class II, III, and IV, including C2β, Vps34, DNA-PK, and mTOR. GDC-0941 potently inhibits the phosphorylation of Akt in U87MG, PC3, and MDA-MB-361 cells with IC50 of 46 nM, 37 nM, and 28 nM, respectively. GDC-0941 inhibits the proliferation of U87MG, A2780, PC3, and MDA-MB-361 cells with IC50 of 0.95 μM, 0.14 μM, 0.28 μM, and 0.72 μM, respectively. [1] GDC-0941 treatment potently inhibits the proliferation of both trastuzumab-sensitive and -insensitive HER2-amplified cells with IC50 of 149-944 nM. GDC-0941 inhibits proliferation of HER2-amplified cells that harbor PIK3CA mutations with IC50 of <500 nM, and effectively inhibits both proliferation and viability of HER2-amplified breast cancer cells that are resistant to trastuzumab due to PTEN loss. [2] GDC-0941 significantly inhibits the growth of HCT116, DLD1 and HT29 cells with GI50 of 1081 nM, 1070 nM and 157 nM, respectively. [3] GDC-0941 inhibits tumor cell proliferation, induces apoptosis and suppresses centroblast population. [4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Sf9 MXPLbY5ie2ViQYPzZZk> M1rnfFEhcA>? MVLEUXNQ MUXJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KFCLM1ugdFEyOGSnbIThJIV5eHKnc4Pl[EBqdiCVZkmgZ4VtdHNiY3;lfJBz\XO|aX7nJJA5PWGucHjhJJdqfGhiSVO1NEBw\iByLkCwN{DPxE1? NGLoeGgyQDd3NE[1OC=>
Sf9 MYHLbY5ie2ViQYPzZZk> MV2xJIg> NHTBRWtFVVOR MlzBTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCSSUPLJJAyOTCkZYThJGgyODR5LWKgcZV1[W62IHX4dJJme3OnZDDpckBU\jliY3XscJMh[2:neIDy[ZN{cW6pIIC4OYFteGijIIfpeIghUUN3MDDv[kAxNjByMzFOwG0> MnzDNVg4PTR4NUS=
Sf9 MVvLbY5ie2ViQYPzZZk> M2rEZVEhcA>? M2jvbmROW09? MXHJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KFCLM1ugdFEyOGKndHGgSVU1PS2NIH31eIFvfCCneIDy[ZN{\WRiaX6gV4Y6KGOnbHzzJINw\XiycnXzd4lv\yCyOEXhcJBp[SC5aYToJGlEPTBib3[gNE4xODNizszN MlfCNVg4PTR4NUS=
Sf9 NF;uPHpMcW6jc3WgRZN{[Xl? NV;NeHJTOSCq MWXEUXNQ NWXu[pZuUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDQTVNMKHBzMUDi[ZRiKGW6cILld5Nm\CCrbjDT[lkh[2WubIOgZ49mgHC{ZYPzbY5oKHB6NXHsdIhiKHerdHigTWM2OCCxZjCwMlA{OyEQvF2= M1n0N|E5PzV2NkW0
Sf9 NV7kUZdPU2mwYYPlJGF{e2G7 MVWxJIg> MWnEUXNQ NVTiNG41UW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDQTVNMKHBzMUDhcJBp[SCneIDy[ZN{\WRiaX6gV4Y6KGOnbHzzJINw\XiycnXzd4lv\yCyOEXhcJBp[Q>? MXKxPFc2PDZ3NB?=
MDA-MB-361 MVPGeY5kfGmxbjDBd5NigQ>? NGTOS2gzKGh? NXP5S41{TE2VTx?= MXnJcohq[mm2aX;uJI9nKEGtdDDT[ZI1PzNicHjvd5Bpd3K7bHH0bY9vKGmwIHj1cYFvKE2GQT3NRk0{PjFiY3XscJMhf2m2aDDQTWs{S0FiRUW0OU1MKG23dHH0bY9vKHerdHigTWM2OCCxZjCwMlAzQCEQvF2= NGnrfoYyQDd3NE[1OC=>
PC3 M1jLSWZ2dmO2aX;uJGF{e2G7 NXPrfZpbOiCq NUfBblNSTE2VTx?= NHLGRZBKdmirYnn0bY9vKG:oIFHreEBU\XJ2N{OgdIhwe3Cqb4L5cIF1cW:wIHnuJHBVTU5vboXscEBpfW2jbjDQR|Mh[2WubIOge4l1cCCLQ{WwJI9nKDBwMEO3JO69VQ>? NIryXmoyQDd3NE[1OC=>
U87MG Mn7FSpVv[3Srb36gRZN{[Xl? NUnleWhTOiCq MoTpSG1UVw>? NYrofYZJUW6qaXLpeIlwdiCxZjDBb5QhW2W{NEezJJBpd3OyaH;yfYxifGmxbjDpckBRXEWQLX71cIwhcHWvYX6gWVg4VUdiY3XscJMhf2m2aDDJR|UxKG:oIECuNFQ3KM7:TR?= Ml7VNVg4PTR4NUS=
MDA-MB-361 MlfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml:5PVYhcA>? M1PlR2ROW09? M1S2WGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVTBMW1DNTN4MTDj[YxteyC5aYToJHBKUzOFQTDFOVQ2NUtibYX0ZZRqd25id3n0bEBKSzVyIH;mJFAvPzJizszN MkDJNVg4PTR4NUS=
A2780 NF\IR4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUK5OkBp M4\ENGROW09? NFO1d|FCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFGyO|gxKGOnbHzzJJdqfGhiUFnLN2NCKGGwZDDQWGVPKG23dHH0bY9vKHerdHigTWM2OCCxZjCwMlE1KM7:TR?= M3uyTFE5PzV2NkW0
PC3 M1:xZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3zOGo6PiCq M2e2cGROW09? MWrJR|UxRTBwMkig{txO Mn[3NVg4PTR4NUS=
U87MG M3fZVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHHeG5HQTZiaB?= NELvPXNFVVOR MknzTWM2OD1yLkm1JO69VQ>? NHrvSYgyQDd3NE[1OC=>
Sf9 MlXjT4lv[XOnIFHzd4F6 NY\vdY9zOzBibXnu M3jG[GROW09? MWXJcohq[mm2aX;uJI9nKGi3bXHuJHBKO0upYX3tZUBmgHC{ZYPz[YQh[XO|ZYPz[YQh[XNiYX3veY51KG:oIFHUVEBkd26|dX3l[EB4cXSqIFnDOVAhd2ZiMD6wOFIh|ryP MlTINlI2PDh|NEK=
RAW 264.7 MV7LbY5ie2ViQYPzZZk> NESwd5I6OCCvaX6= M1\nR2ROW09? M3\WZ2lvcGmkaYTpc44hd2ZiaIXtZY4hWEl|S3fhcY1iKGW6cILld5Nm\CCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKEGNVDDwbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFAvOjl6IN88US=> M2TOZVIzPTR6M{Sy
Sf9 MUXLbY5ie2ViQYPzZZk> M{\TN|EhcA>? NULifGhmUW6qaXLpeIlwdiCxZjDHV3Qu\nW|ZXSgbJVu[W5icnXjc41jcW6jboSgVGk{U2KndHGg[ZhxemW|c3XkJIlvKGKjY4Xsc5ZqenW|IHnu[oVkfGWmIGPGPUBk\WyuczD3bZRpKEmFNUCgc4YhOC5yMUeg{txO NYjHfpRkOjN3NEC2OFU>
Sf9 M{foTmtqdmG|ZTDBd5NigQ>? NYCwR5BzOSCq NYniXFd4UW6qaXLpeIlwdiCxZjDHV3Qu\nW|ZXSgbJVu[W5icnXjc41jcW6jboSgVGk{U2SnbIThJIV5eHKnc4Pl[C=> MkLsNlM2PDB4NEW=
Sf9 NUnCU2g4U2mwYYPlJGF{e2G7 M3u4eVEhcA>? NYq3fGVGUW6qaXLpeIlwdiCxZjDHV3Qu\nW|ZXSgbJVu[W5icnXjc41jcW6jboSgVGk{U2ejbX3hJIV5eHKnc4Pl[C=> NYPuVGViOjN3NEC2OFU>
Sf9 MVTLbY5ie2ViQYPzZZk> MoPLNUBp NUHmOoZDUW6qaXLpeIlwdiCxZjDHV3Qu\nW|ZXSgbJVu[W5icnXjc41jcW6jboSgVGk{U2GucHjhJIV5eHKnc4Pl[C=> NYi5SVFrOjN3NEC2OFU>
SKOV3 NVTuclVNU2mwYYPlJGF{e2G7 MYexJO69VQ>? MmjJNUBp NXTK[ohHTE2VTx?= MWfJcohq[mm2aX;uJI9nKFCLM1vhcJBp[SCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKEGtdDDT[ZI1PzNicHjvd5Bpd3K7bHH0bY9v MkDYNlM{PjB|NEi=
MCF7 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLwN3gyKM7:TR?= NFrNfpE6PiCq NF\oWmVFVVOR NH\CXJZIUTVyPUCuNFcxOiEQvF2= MmjqNlM{PjB|NEi=
SKOV3 M{Pocmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7QNUDPxE1? NHLaN4I6PiCq Ml74SG1UVw>? NGTzZnNIUTVyPUCuNVQ4PiEQvF2= MlH5NlM{PjB|NEi=
PC3 NH[x[mpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVG3NkBp Mnv2SG1UVw>? NY\Ic5RMUUN3ME2wMlI5KM7:TR?= NFzZPYUzOTl6MUexOC=>
MCF7.1 NFLZRYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLpdlJ5PzJiaB?= NGLkdWZFVVOR MYfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkeuNUBk\WyuczDlfJBz\XO|aX7nJGhGWjJiZ3Xu[UB4cXSqIFnDOVAhd2ZiMD6yPEDPxE1? NYfrWHZqOjF7OEG3NVQ>
MCF7-neo/Her2 M1XsPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XCflczKGh? NYL2RmU3TE2VTx?= MoDITWM2OD1yLkK5JO69VQ>? M2XMclI{PjZ{OUCz
MCF7-neo/Her2 NXrJS4NDU2mwYYPlJGF{e2G7 NWPPbmx4UW6qaXLpeIlwdiCxZjDQTVNM[WyyaHGgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKG:oIFHLWEBxcG:|cHjvdplt[XSrb36gZZQhWzR5MzD3bZRpKEmFNUCgc4YhOC5yMEeg{txO NGXNPWYzOzZ4MkmwNy=>
PC3 M4r0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;JO|IhcA>? MnjhSG1UVw>? NUHZc3RwTUN3ME2wMlM1KM7:TR?= NYqxWIVFOjF7OEW2N|k>
MCF7.1 NXzHfYtHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWW3NkBp MVnEUXNQ M1vMXmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{4yKGOnbHzzJIV5eHKnc4PpcochWEl|S3HsdIhiKG23dHHueEB4cXSqIFXDOVAhd2ZiMD6zPUDPxE1? NIHmbJIzOTl6NU[zPS=>
PC3 Mki5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXu3NkBp MVrEUXNQ NUfvbHRzSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDQR|Mh[2WubIOg[IVncWOrZX70JIlvKFCWRV6ge4l1cCCLQ{WwJI9nKDBwM{mg{txO MmTRNlAxPTB4Nkm=
MCF7.1 M3P6cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUC3NkBp MnPtSG1UVw>? MXvBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkeuNUBk\WyuczDlfJBz\XO|aX7nJHBKO0ujbIDoZUBufXSjboSge4l1cCCLQ{WwJI9nKDBwM{Sg{txO Ml;3NlAxPTB4Nkm=
MCF7.1 NWrFPINxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXlO|IhcA>? NHTDeJFGSzVyPUCuO|Ih|ryP MVOyNFM1PjZ3Nh?=
NCI-H1975 NF\keJBEgXSxdH;4bYMhSXO|YYm= M4\oVVczKGh? MkDrTWM2OD1yLkK3JO69VQ>? NWPHVIZIOjNyNUm1OFU>
H460 M2XRVWN6fG:2b4jpZ{BCe3OjeR?= NXT0XHpUPzJiaB?= MkDETWM2OD1yLki3JO69VQ>? NFHyUVgzOzB3OUW0OS=>
HT-29 M4r3UGN6fG:2b4jpZ{BCe3OjeR?= NHK3SJE4OiCq MlP1TWM2OD1yLk[2JO69VQ>? MnPhNlMxPTl3NEW=
HepG2 NHm0V3lEgXSxdH;4bYMhSXO|YYm= MWG3NkBp NHXBPJhKSzVyPUGg{txO MWGyN|A2QTV2NR?=
SGC7901 NYr6Zpd5S3m2b4TvfIlkKEG|c3H5 NWLJfWxQPzJiaB?= NGexS|dKSzVyPUGuPEDPxE1? M3HSeFI{ODV7NUS1
NCI-H226 NGnJfWxEgXSxdH;4bYMhSXO|YYm= MUC3NkBp NGmzU|hKSzVyPUKuPUDPxE1? NFvoU3kzOzB3OUW0OS=>
A549 MVTDfZRwfG:6aXOgRZN{[Xl? NXzwbVVRPzJiaB?= MmCxTWM2OD14Lkmg{txO M{DrNFI{ODV7NUS1
U87MG MVTDfZRwfG:6aXOgRZN{[Xl? NInme4c4OiCq MX7JR|UxRTdwN{eg{txO M3nqcFI{ODV7NUS1
HBC4 MnvwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\sc4dIUTVyPT22MlA{KE1? MUCyNlM{PjJ2Nh?=
BSY1 NHv3WFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\vcI9oT0l3ME2tOk46OCCP MXuyNlM{PjJ2Nh?=
HBC5 NGXQVZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml:wcI9oT0l3ME2tOk43OCCP M1rYUlIzOzN4MkS2
MCF7 NH65[ZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PQbIxw\0eLNUC9MVcvOzNiTR?= Mn\6NlI{OzZ{NE[=
MDA-MB-231 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV21XnJFdG:pR1m1NF0uPS52NjDN NXjKWJQ3OjJ|M{[yOFY>
U251 NYXVXGxYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\1cI9oT0l3ME2tOU42OCCP M4jHVlIzOzN4MkS2
SF268 NIn6dI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIr4[ZFtd2eJSUWwQU02NjN7IF2= M3jHeVIzOzN4MkS2
SF295 NUW3VY5XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HBSIxw\0eLNUC9MVYvOzdiTR?= NILrfIUzOjN|NkK0Oi=>
SF539 NXrEdIttT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVGw[pB1dG:pR1m1NF0uPi53MDDN M3fDR|IzOzN4MkS2
SNB75 MkfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7wcI9oT0l3ME2tO{4yOCCP MWiyNlM{PjJ2Nh?=
SNB78 NFPNUG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPsc4dIUTVyPT22MlUzKE1? MWCyNlM{PjJ2Nh?=
HCC2998 NXS1XXVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkP0cI9oT0l3ME2tOk4zQSCP NWfkOJRVOjJ|M{[yOFY>
KM12 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTsc4dIUTVyPT21Mlc3KE1? MljPNlI{OzZ{NE[=
HT-29 M4XnUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjBfI41dG:pR1m1NF0uPi5|MDDN NXHjRnVvOjJ|M{[yOFY>
HCT15 NGDqcolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTEcI9oT0l3ME2tOk4yOiCP M1faTFIzOzN4MkS2
HCT116 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4L0R4xw\0eLNUC9MVUvQDdiTR?= MorENlI{OzZ{NE[=
NCI-H23 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDsc4dIUTVyPT21Mlc{KE1? NXvQc3FwOjJ|M{[yOFY>
NCI-H226 NF\4cZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHe5VpVtd2eJSUWwQU03NjJzIF2= NWnHNYJFOjJ|M{[yOFY>
NCI-H522 NYf2O4U6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXucI9oT0l3ME2tOk42QCCP MYOyNlM{PjJ2Nh?=
NCI-H483 NH34e2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fyUYxw\0eLNUC9MVYvPTZiTR?= NXHqW|VbOjJ|M{[yOFY>
A549 M4HENmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPJdXpudG:pR1m1NF0uPi5zNTDN NVnQUlhZOjJ|M{[yOFY>
DMS273 NH;PWZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHtbYRtd2eJSUWwQU03NjR|IF2= MXiyNlM{PjJ2Nh?=
DMS114 NUfIR20yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzsc4dIUTVyPT21MlkzKE1? M3;VWlIzOzN4MkS2
LOXIMVI NV7LV5FIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;JUoxw\0eLNUC9MVYvOjliTR?= MnjLNlI{OzZ{NE[=
OVCAR3 M{nOc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzZclhtd2eJSUWwQU03NjdzIF2= M13BO|IzOzN4MkS2
OVCAR4 NEPCV4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkL2cI9oT0l3ME2tOU44PiCP NFHwdJYzOjN|NkK0Oi=>
OVCAR5 NH;v[2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\GcI9oT0l3ME2tOk4zPiCP MUSyNlM{PjJ2Nh?=
OVCAR8 M4W1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHsc4dIUTVyPT21Mlc{KE1? NEXnWmUzOjN|NkK0Oi=>
SKOV3 MkSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPsc4dIUTVyPT22MlUzKE1? NEPNTGUzOjN|NkK0Oi=>
RXF631L NVv1[WZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjKPGRydG:pR1m1NF0uPi56ODDN NXO3V4VMOjJ|M{[yOFY>
ACHN MnXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLCcI9oT0l3ME2tOk4xPyCP M2X1d|IzOzN4MkS2
St-4 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;TdWttd2eJSUWwQU02NjV4IF2= NY\2ZWFKOjJ|M{[yOFY>
MKN1 NXSxV|U1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzuPIxtd2eJSUWwQU04NjB6IF2= MnWwNlI{OzZ{NE[=
MKN7 NWq1TGs5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLDSHoydG:pR1m1NF0uPi53MDDN M1ezfFIzOzN4MkS2
MKN28 NHr0eIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnsc4dIUTVyPT21MlUzKE1? M{PFXFIzOzN4MkS2
MKN45 M3[4UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDKcI9oT0l3ME2tOk42PSCP NF;RSZAzOjN|NkK0Oi=>
MKN74 NXHtUVI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoC3cI9oT0l3ME2tOk4xOiCP NIj0cHQzOjN|NkK0Oi=>
DU145 NUG5UnNbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjlc4xtd2eJSUWwQU02Njh3IF2= NVLqUVl1OjJ|M{[yOFY>
PC3 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPsc4dIUTVyPT22MlY3KE1? NUnpRmlQOjJ|M{[yOFY>
ES5 M4O0S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXabINKSzVyPUWwMlIyKG6P MVjTRW5ITVJ?
HH NXXmVnlMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLyO2tKSzVyPUGxNU4xQCCwTR?= NYPaRlVDW0GQR1XS
MHH-PREB-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXITWM2OD1zMUSuN{BvVQ>? NIPU[4xUSU6JRWK=
NCI-H1770 NHL4d4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXFcZFtUUN3ME2xNlMvQDZibl2= NVH2TJZjW0GQR1XS
HuO9 NF7Ec5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm[zTWM2OD1{ME[uNFIhdk1? NFe1VlRUSU6JRWK=
HAL-01 M1r1Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTJyNj63N{BvVQ>? MVvTRW5ITVJ?
NOS-1 MmX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTJzMT64NkBvVQ>? NFWwe25USU6JRWK=
HGC-27 NFe2UplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fV[mlEPTB;MkGyMlU4KG6P M4LCU3NCVkeHUh?=
NB69 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrhXFFmUUN3ME2yOFUvOjdibl2= MY\TRW5ITVJ?
RS4-11 NFP1XZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofrTWM2OD1{NkGuO|Yhdk1? M4G4WnNCVkeHUh?=
DOK MmDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTNyMT63JI5O M2X0cnNCVkeHUh?=
LB2241-RCC NXT0O4JpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofTTWM2OD1|MEOuPFQhdk1? M4L2XXNCVkeHUh?=
NCI-H1623 NV;K[XRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;rTWM2OD1|MESuNFghdk1? NE\iTodUSU6JRWK=
YH-13 NEG4VFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLq[noxUUN3ME2zNFQvOzJibl2= NELPZ2VUSU6JRWK=
BPH-1 NGjyd|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTNzNDDuUS=> M3;KXHNCVkeHUh?=
AN3-CA MlnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1S2W2lEPTB;M{SwMlM4KG6P NYTHUGpUW0GQR1XS
ES7 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\qe2lSUUN3ME2zOFEvQTlibl2= NXzi[|F2W0GQR1XS
MDA-MB-175-VII MnG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonBTWM2OD1|NUKuPVIhdk1? M4H1eXNCVkeHUh?=
GAMG M3vlRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3O4dGlEPTB;M{ewMlg2KG6P MlzuV2FPT0WU
CHL-1 Mo\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXBTWM2OD1|N{iuOlUhdk1? NVi2N2ZmW0GQR1XS
NB7 NYPMZ4N7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfjTWM2OD1|OEmuPFMhdk1? NIHjRVlUSU6JRWK=
MFE-280 NFvaNZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\sTWM2OD12MUiuNkBvVQ>? M3i1VnNCVkeHUh?=
HL-60 MkPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\ZPGlEPTB;NEK1Mlc2KG6P NWfDT|V5W0GQR1XS
GCIY MmOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTR|Mz64JI5O Mme1V2FPT0WU
MDA-MB-361 NEHPTmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTl[YhKSzVyPUSzPU4yOyCwTR?= MUjTRW5ITVJ?
LXF-289 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTR2OD6yO{BvVQ>? NGLSUmZUSU6JRWK=
NBsusSR MmroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHSwfIpKSzVyPUS4PE45PSCwTR?= MXzTRW5ITVJ?
KU-19-19 M3ziNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnQSYY2UUN3ME21NVYvODdibl2= NIHWUVBUSU6JRWK=
A204 NFHHW3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TubWlEPTB;NUKyMlM{KG6P NG\m[XRUSU6JRWK=
LB1047-RCC MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnm5TWM2OD13MkKuPVMhdk1? NEf6TmhUSU6JRWK=
COLO-684 NF3relJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljoTWM2OD13MkOuNVEhdk1? MVjTRW5ITVJ?
PA-1 MoW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXofW9KSzVyPUWzNk41OSCwTR?= NInJWHNUSU6JRWK=
MG-63 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HZbmlEPTB;NUSxMlEyKG6P M2rMR3NCVkeHUh?=
BHT-101 NUi3TWRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HwcGlEPTB;NUS0Mlk1KG6P MUXTRW5ITVJ?
NKM-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPhUoI1UUN3ME21PVMvODlibl2= M2roVXNCVkeHUh?=
T47D MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\SR3ZKSzVyPUW5O{42PiCwTR?= MVXTRW5ITVJ?
MOLT-4 NFTQPHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TB[GlEPTB;NkKzMlYzKG6P MoPPV2FPT0WU
IGROV-1 M{i2O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\BTWM2OD14M{SuN|Ehdk1? Ml;oV2FPT0WU
ES4 M4nyfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PSZ2lEPTB;NkO5MlU1KG6P MkewV2FPT0WU
HuO-3N1 MnXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrMTWM2OD14NEKuN|ghdk1? NUTSO4ZXW0GQR1XS
NEC8 Mmq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4e4[2lEPTB;NkWzMlU4KG6P MmHQV2FPT0WU
HO-1-N-1 Ml65S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHGSIlrUUN3ME22OVkvOTdibl2= NX3S[GVXW0GQR1XS
EPCL-272H MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGr2W3FKSzVyPU[4O{4zOSCwTR?= MUHTRW5ITVJ?
D-263MG Mn3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXGZYdKSzVyPUexPE4yKG6P MnLTV2FPT0WU
MV-4-11 NEnHUHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXCdmFKSzVyPUeyOE4{OSCwTR?= NX7oNHV5W0GQR1XS
SK-NEP-1 NVPjXo9qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHiwdYlKSzVyPUeyOU46PCCwTR?= MWXTRW5ITVJ?
SW872 NVfzTGdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{D3S2lEPTB;N{K3Mlg6KG6P NF3qU|VUSU6JRWK=
P30-OHK M1nwWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXmSJpKSzVyPUezNE44OSCwTR?= M2LDVnNCVkeHUh?=
OMC-1 M1f2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITySoVKSzVyPUe1NU4xQSCwTR?= NUe4TZhUW0GQR1XS
LoVo NWfpTZVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXUTWM2OD15N{euPUBvVQ>? NUT4[FlJW0GQR1XS
LNCaP-Clone-FGC M1uzcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnm2TWM2OD15OU[uN|Qhdk1? Mn7EV2FPT0WU
L-363 NF\YW3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPVeFNKSzVyPUe5PE41OiCwTR?= MlX3V2FPT0WU
ES8 M1myR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRThzMD61NkBvVQ>? M2TCbHNCVkeHUh?=
697 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrMSY5KSzVyPUizNU42PSCwTR?= NHvmR5NUSU6JRWK=
HSC-3 MnjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HMVmlEPTB;OEO5MlU1KG6P M4jpeHNCVkeHUh?=
H4 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTh3MD64OUBvVQ>? NIHMRppUSU6JRWK=
QIMR-WIL M4LvU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFGzVnFKSzVyPUi2OU4zKG6P NWHo[4ZsW0GQR1XS
OAW-42 NVH3S29QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\FdoxmUUN3ME24O|IvOTlibl2= M2f4[HNCVkeHUh?=
MCF7 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTh7OD61PUBvVQ>? MWLTRW5ITVJ?
SCC-25 M2D6[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XDUGlEPTB;OUG0MlE6KG6P NYHIc5BFW0GQR1XS
NCI-H1563 M1jvPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTlzNT65PUBvVQ>? NHyxZlZUSU6JRWK=
OVCAR-5 NGXmPW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknLTWM2OD17NECuNVchdk1? NHXLTFZUSU6JRWK=
HDLM-2 M1jj[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrUTWM2OD17NEmuNkBvVQ>? M4G2NXNCVkeHUh?=
NB5 NFvBdYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILpRZNKSzVyPUm1Ok43KG6P M3vWbXNCVkeHUh?=
NCI-H292 NEDSXZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTl5ND6zNkBvVQ>? MU\TRW5ITVJ?
A101D Mn\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojmTWM2OD17OUCuNVkhdk1? M4Kz[3NCVkeHUh?=
NCI-H1648 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HLUGlEPTB;OUm4MlUyKG6P MorDV2FPT0WU
EKVX NXjRUI8zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTFwMEGyPUDPxE1? NXrITpZjW0GQR1XS
SW1710 MkLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{e5fGlEPTB;MT6wOFI{OyEQvF2= M4LyenNCVkeHUh?=
WM-115 NXTVSlJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXNTWM2OD1zLkC2OlU3KM7:TR?= NVjSNI1JW0GQR1XS
CAL-54 MnrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rKdGlEPTB;MT6wO|A5OSEQvF2= MUXTRW5ITVJ?
TGBC24TKB NH33V3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTFwMEiwOFUh|ryP M3;rU3NCVkeHUh?=
NCI-H520 M4Xvbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3USldVUUN3ME2xMlA5QTZ5IN88US=> MWfTRW5ITVJ?
D-423MG MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTFwMEm5OlIh|ryP MmL0V2FPT0WU
BFTC-905 NFjJRnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TKbWlEPTB;MT6xN|Q1QSEQvF2= Mn7TV2FPT0WU
HT M1PiV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDMTWM2OD1zLkGzOFc5KM7:TR?= MUnTRW5ITVJ?
CTB-1 NYTzWZBWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\HTWM2OD1zLkG0Nlk{KM7:TR?= M37EZXNCVkeHUh?=
Hs-578-T MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7WOZpKSzVyPUGuNVk2PjVizszN NF\Tc2VUSU6JRWK=
HuH-7 NFfpZXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLoT4FKSzVyPUGuNlA6PDlizszN M4rBXHNCVkeHUh?=
LB996-RCC NXS5bXpbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrQTWM2OD1zLkKyNVc4KM7:TR?= NVL6NWJMW0GQR1XS
KYSE-270 MlK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1L3fmlEPTB;MT6yPVc{PCEQvF2= MlTRV2FPT0WU
A4-Fuk NHL2fG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLT[GZQUUN3ME2xMlI6QTl|IN88US=> MYrTRW5ITVJ?
A498 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDVTWM2OD1zLkOwOFc1KM7:TR?= MoPxV2FPT0WU
SK-MEL-1 NEDId2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTFwM{C2O|kh|ryP NVvucVRnW0GQR1XS
AU565 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTFwM{G4OlMh|ryP MXHTRW5ITVJ?
Saos-2 NF2zSoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEH4Z5ZKSzVyPUGuN|MzODVizszN MlnOV2FPT0WU
A549 MmC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHaTWM2OD1zLkO5PVch|ryP NVvjTnhkW0GQR1XS
BFTC-909 NEXSN2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;3TWM2OD1zLkSzN|A2KM7:TR?= NH3TeJJUSU6JRWK=
MDA-MB-415 NU\qOIFRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zlbmlEPTB;MT60PFY6OiEQvF2= NF\ZT2VUSU6JRWK=
639-V MnfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTFwNUCyOFUh|ryP NVPPSHJmW0GQR1XS
A704 NE\HfIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nNV2lEPTB;MT61NFc5PSEQvF2= MnTXV2FPT0WU
PANC-03-27 NFjKUJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4m3N2lEPTB;MT61NVQxQCEQvF2= MlLDV2FPT0WU
SK-MEL-28 MkTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULQflRLUUN3ME2xMlU3ODh3IN88US=> NEP6eZBUSU6JRWK=
Ramos-2G6-4C10 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fU[2lEPTB;MT62NFc1PiEQvF2= M4nhRnNCVkeHUh?=
HuP-T4 M3HUd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvoTplKSzVyPUGuOlA4PzhizszN NEjRTI5USU6JRWK=
VA-ES-BJ NVPDNldMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHidlVKSzVyPUGuOlEzPyEQvF2= Ml;JV2FPT0WU
EFM-19 M37QRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4T4N2lEPTB;MT62NVgyKM7:TR?= NFn0cGVUSU6JRWK=
G-401 M4fpVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX:1TVN7UUN3ME2xMlYzOTZ2IN88US=> M4jZcXNCVkeHUh?=
D-566MG M{PGTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rENGlEPTB;MT62NlU{KM7:TR?= MnO1V2FPT0WU
JVM-3 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDHZldKSzVyPUGuOlQ5PzVizszN M2qybnNCVkeHUh?=
TK10 NITtfFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvmSpNKSzVyPUGuOlcxQDNizszN NHO5fppUSU6JRWK=
BT-20 MkTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTFwNki5NFIh|ryP MUPTRW5ITVJ?
EGI-1 NIjLcWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrHdG9iUUN3ME2xMlg1PzBzIN88US=> NXTYdHVXW0GQR1XS
EW-16 M2C3Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnO1TWM2OD1zLki1NVgzKM7:TR?= M1LOTXNCVkeHUh?=
NCI-H2228 MnrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLNTWM2OD1zLki1NlA{KM7:TR?= NWf6V2d7W0GQR1XS
BB49-HNC M{DUNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHC[nJKSzVyPUGuPFg3QTJizszN M4LYT3NCVkeHUh?=
G-402 NVHkZmJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTFwOEm3PVch|ryP MnzZV2FPT0WU
NCI-H526 NH;0clZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXQS25KSzVyPUGuPVE{QSEQvF2= NEHSZXdUSU6JRWK=
ME-180 M3rtUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7QZ5dKSzVyPUGuPVM1PzdizszN M3zIR3NCVkeHUh?=
PFSK-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXOSGJKSzVyPUGuPVQ1PThizszN MoDjV2FPT0WU
TYK-nu MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXpTWM2OD1zLkm1PFI{KM7:TR?= M{G1UXNCVkeHUh?=
HOS MnXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzMZpFiUUN3ME2xMlk4QTR6IN88US=> MVvTRW5ITVJ?
T98G MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHVTWM2OD1zLkm5NFA3KM7:TR?= MWfTRW5ITVJ?
SK-MES-1 NUPpXmFPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{j1bmlEPTB;Mj6wNVM{OiEQvF2= MV;TRW5ITVJ?
SNB75 NYWwb|BsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnW0TWM2OD1{LkCxOVQyKM7:TR?= Mn;QV2FPT0WU
LAMA-84 M4frW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;hTXBKSzVyPUKuNFI3QDlizszN MWfTRW5ITVJ?
CAL-39 NFSzVI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjEPHRKSzVyPUKuNFMzQCEQvF2= MnXsV2FPT0WU
LOXIMVI NGDOXHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTJwMESwPFQh|ryP NYTlcmNLW0GQR1XS
NH-12 M1HGNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDzTWM2OD1{LkC1OFI1KM7:TR?= MoXaV2FPT0WU
NCI-H1048 MlSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDrTWM2OD1{LkGwOVIh|ryP NHH6XJNUSU6JRWK=
KS-1 NEHO[2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTJwMUGwNFEh|ryP MlrJV2FPT0WU
NCI-N87 NWe0VIhqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTJwMUOzPFQh|ryP M3j2eXNCVkeHUh?=
CHP-212 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTJwMUi0OFIh|ryP M3nPc3NCVkeHUh?=
HCC1419 NWHDTm9qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLvWZVwUUN3ME2yMlIyOTF3IN88US=> MlHvV2FPT0WU
ES1 M1TKb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTJwMkGzNlYh|ryP MWjTRW5ITVJ?
NCI-H2030 NEG5[G5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXj2U3A5UUN3ME2yMlI1OTJ|IN88US=> M3TWS3NCVkeHUh?=
EW-22 NGXP[GZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3O3ZmlEPTB;Mj6yOVA3PyEQvF2= M3\2XXNCVkeHUh?=
A431 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTJwMkezOVQh|ryP NHHzVVFUSU6JRWK=
SF126 M2[1[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTJwM{C2NlUh|ryP NIfzcWFUSU6JRWK=
SF295 M4rLSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPuO4ZPUUN3ME2yMlMyPTJ2IN88US=> MoKyV2FPT0WU
D-502MG NXvWXGxTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;rVmlEPTB;Mj6zNlQ3OSEQvF2= NX;kWY5wW0GQR1XS
HCC2157 M2m3emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXmWlBwUUN3ME2yMlMzQTJ5IN88US=> NVHNW3pZW0GQR1XS
D-283MED NVm5[Ik3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmj1TWM2OD1{LkO1PVI3KM7:TR?= M1PjeHNCVkeHUh?=
SNU-423 MlzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXZTWM2OD1{LkSwNVcyKM7:TR?= M{jOU3NCVkeHUh?=
SK-LU-1 MoPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HTW2lEPTB;Mj60OFU5PiEQvF2= MnXGV2FPT0WU
22RV1 NFnhZXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13zZmlEPTB;Mj60OVYyPyEQvF2= MnvRV2FPT0WU
SW1088 M3OyRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkX4TWM2OD1{LkS5NlE{KM7:TR?= MlXiV2FPT0WU
HT-3 NEH0U4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzNTWM2OD1{LkS5NlU6KM7:TR?= MX7TRW5ITVJ?
NCI-H1666 M1\ZbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\nTWM2OD1{LkWxNVA1KM7:TR?= MUnTRW5ITVJ?
EM-2 M2fBUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU[xdY5mUUN3ME2yMlUyOTZ7IN88US=> M1O0ZXNCVkeHUh?=
SNU-449 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvlTWM2OD1{LkW3NFE1KM7:TR?= NIKxdJZUSU6JRWK=
786-0 NYPxbXl1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTJwNUmyN|gh|ryP MmrtV2FPT0WU
SKG-IIIa NH6wbGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\TOphrUUN3ME2yMlY2QTN7IN88US=> MXrTRW5ITVJ?
MEL-HO NEfZXmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTJwNke2N|Qh|ryP M1iwOXNCVkeHUh?=
LCLC-97TM1 Mn\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3G2cmlEPTB;Mj62PVI3PyEQvF2= MYPTRW5ITVJ?
MKN7 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nKT2lEPTB;Mj63NFc2PCEQvF2= M4Hk[HNCVkeHUh?=
5637 NEDpRpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HGdGlEPTB;Mj63NVA{PSEQvF2= NYHv[Zc{W0GQR1XS
HOP-92 MmD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTJwN{S3NVch|ryP NVj0OXVbW0GQR1XS
MDA-MB-157 Mn;hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIT0ZXRKSzVyPUKuPFIxOjNizszN MorIV2FPT0WU
NB12 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;MVppHUUN3ME2yMlg1QTF2IN88US=> NHLJT4tUSU6JRWK=
DMS-273 MkHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEn2eXFKSzVyPUKuPFY1PyEQvF2= MoDGV2FPT0WU
HCC70 MnnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTJwOE[1PFkh|ryP MnX3V2FPT0WU
YKG-1 NFLwUI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HwXmlEPTB;Mz6wN|c5PyEQvF2= NUXsNW9EW0GQR1XS
NCI-H28 NWe1VVNqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rGVGlEPTB;Mz6wOVI6OSEQvF2= NUfTbmM2W0GQR1XS
HN NH\wXVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoS3TWM2OD1|LkC2OlM3KM7:TR?= NWDCdpRJW0GQR1XS
HT-1080 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHlfFBOUUN3ME2zMlA5PjB4IN88US=> NE\SdoRUSU6JRWK=
HPAF-II M{njRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInEUXZKSzVyPUOuNVAxPjhizszN NVfNOZA2W0GQR1XS
U-2-OS MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljLTWM2OD1|LkGzO|gzKM7:TR?= MoPDV2FPT0WU
SNU-387 M{m0VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPJTWM2OD1|LkG2N|Y1KM7:TR?= NUjJZWw3W0GQR1XS
Becker MlfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX24doI4UUN3ME2zMlE3QDB6IN88US=> M{D5b3NCVkeHUh?=
BHY M4fqZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHz5TI9KSzVyPUOuNlU2PzFizszN Mme0V2FPT0WU
HTC-C3 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fvXmlEPTB;Mz6yPVM2OiEQvF2= NWLRW4NsW0GQR1XS
M14 NWXRNFBGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTNwM{C2OlMh|ryP NIC5XYJUSU6JRWK=
COR-L23 MnixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY[5cmtwUUN3ME2zMlM4Ojd7IN88US=> M{TyS3NCVkeHUh?=
C32 NGO4RVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1f3U2lEPTB;Mz60NVUxQCEQvF2= MULTRW5ITVJ?
Mewo M3LLdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIi4NZVKSzVyPUOuOFIyQDJizszN NF62NGdUSU6JRWK=
TE-8 M3vEUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\UTWM2OD1|LkS4NlU6KM7:TR?= NEH0ToVUSU6JRWK=
RPMI-2650 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHryU4VKSzVyPUOuOlA3OzdizszN NITveFFUSU6JRWK=
AGS NWfPSo9HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\4TWM2OD1|Lk[yOFY1KM7:TR?= NFnpTmhUSU6JRWK=
MZ2-MEL MoTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPCZnZxUUN3ME2zMlY3OTN6IN88US=> M1XsdnNCVkeHUh?=
Calu-3 MlzSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGX4RZBKSzVyPUOuO|EzQDdizszN Mm[3V2FPT0WU
SJSA-1 NE\FTpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWr6NVZZUUN3ME2zMlcyOzF3IN88US=> MmD0V2FPT0WU
SW962 NHrGZo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTNwN{K2N|Yh|ryP M4n0eHNCVkeHUh?=
PC-14 NHjKXlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnOVnRNUUN3ME2zMlc{OjJ{IN88US=> NYrhS2FPW0GQR1XS
SW1573 MnvvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPSfXNKSzVyPUOuO|U{PDhizszN M{\LcnNCVkeHUh?=
769-P MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnn6TWM2OD1|LkiyO|Q{KM7:TR?= NUHMNlF[W0GQR1XS
KNS-62 NW\DNo5ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTNwOUKzN|gh|ryP NGjzXGdUSU6JRWK=
NCI-H747 Mle4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\HNXZJUUN3ME20MlA2PjN6IN88US=> M130WHNCVkeHUh?=
LN-405 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3viWWlEPTB;ND6xOVczQCEQvF2= MlXtV2FPT0WU
OVCAR-8 NVTU[o9MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV70fotqUUN3ME20MlIzPTR|IN88US=> MULTRW5ITVJ?
DMS-114 NULWdGtwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TubGlEPTB;ND6yN|g6OSEQvF2= M4TXN3NCVkeHUh?=
NCI-H2126 MkjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrPWnlKSzVyPUSuNlQ2PThizszN M1z6SnNCVkeHUh?=
TCCSUP MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfzTWM2OD12LkK0O|g5KM7:TR?= NUHOSIJvW0GQR1XS
SK-N-FI NEnnZodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\ZWnU1UUN3ME20MlI2OzN{IN88US=> NYXWbGI1W0GQR1XS
HCE-4 NYewN4dvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTRwMkexPVch|ryP NX3mXohWW0GQR1XS
DK-MG MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjIdIlLUUN3ME20MlMxOzlizszN MX\TRW5ITVJ?
RO82-W-1 NX[5fW8xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFv6[pJKSzVyPUSuN|I2QDRizszN M4HOXHNCVkeHUh?=
A2780 NUfmUIZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXuTWM2OD12LkO2OlgzKM7:TR?= MXTTRW5ITVJ?
ETK-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fLd2lEPTB;ND6zO|A2OiEQvF2= M{XwXnNCVkeHUh?=
FADU MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnKTWM2OD12LkO3OFY4KM7:TR?= NHjrTZBUSU6JRWK=
CAL-12T M4jseGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjCVYdKSzVyPUSuOFE1OTNizszN NFq1cW5USU6JRWK=
647-V Mmj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTRwNESwNlIh|ryP NInyS5pUSU6JRWK=
TGBC1TKB NVzp[3FIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXTTHRoUUN3ME20MlQ2OTF|IN88US=> M2\meHNCVkeHUh?=
LU-99A M3TVN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;KNHRKSzVyPUSuOFYxPiEQvF2= MXfTRW5ITVJ?
CAL-33 NYLoW3YxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHG1XldKSzVyPUSuOVI1PTZizszN MX3TRW5ITVJ?
LU-134-A NIrTUGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfFTWM2OD12LkWyO|Q2KM7:TR?= NYeyWGczW0GQR1XS
NCI-H1355 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTRwNUWxOFYh|ryP NHrENYJUSU6JRWK=
RPMI-7951 NHzpRppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn21TWM2OD12LkW3NFAzKM7:TR?= M4HDb3NCVkeHUh?=
TE-1 M13PXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTRwNk[xOFMh|ryP NVnV[VdIW0GQR1XS
OE33 NXHLZVhPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHwWZlKSzVyPUSuO|A2OTFizszN M1XlXnNCVkeHUh?=
CAL-51 NGrDUplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3L6cGlEPTB;ND63NVA5OiEQvF2= NIixO5ZUSU6JRWK=
SW1783 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTRwN{WzNFgh|ryP MVzTRW5ITVJ?
BT-474 NXXzNHVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3xTWM2OD12Lke2N|g1KM7:TR?= MmjiV2FPT0WU
KYSE-520 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHUNlR1UUN3ME20Mlg4Ozl{IN88US=> NHXjUXFUSU6JRWK=
8-MG-BA NIjETFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTMTnNZUUN3ME20Mlg5PTV5IN88US=> MWfTRW5ITVJ?
IA-LM MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nZNWlEPTB;ND65PVQ{PSEQvF2= M{TQbXNCVkeHUh?=
SW954 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHtNpdKSzVyPUSuPVk1PDNizszN M4HDZ3NCVkeHUh?=
RPMI-8226 MmnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfUOoZ{UUN3ME21MlA2PDZzIN88US=> NETOZ3NUSU6JRWK=
MKN1 NYrBclJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjmVZRUUUN3ME21MlA4QTJ5IN88US=> MX;TRW5ITVJ?
A375 NWPhbpNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnzSXFZUUN3ME21MlA6OjV4IN88US=> Mm\rV2FPT0WU
8305C NUfNR|F6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1S5V2lEPTB;NT6wPVg5PyEQvF2= NVLh[ppMW0GQR1XS
CAL-62 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3SPIp5UUN3ME21MlE5OjV7IN88US=> MlHjV2FPT0WU
NB10 MlXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LEeGlEPTB;NT6yNlc1PCEQvF2= NG\3V5hUSU6JRWK=
OC-314 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nyd2lEPTB;NT6zO|Q1PCEQvF2= Mn;HV2FPT0WU
PSN1 NFvJU5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfEVoV2UUN3ME21MlM5Ojh4IN88US=> MXLTRW5ITVJ?
GR-ST NV[3fmpqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LxN2lEPTB;NT6zPFMzOiEQvF2= NFTPV|JUSU6JRWK=
P12-ICHIKAWA MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTVwNECxJO69VQ>? NGm0e|RUSU6JRWK=
NCI-H1092 Mlv2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jzSWlEPTB;NT60NVE1QCEQvF2= M2\IWnNCVkeHUh?=
SCC-4 NX;tRYJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjyTVBwUUN3ME21MlQyOzV3IN88US=> NIqyR3RUSU6JRWK=
TE-6 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTVwNEG4NVYh|ryP MUPTRW5ITVJ?
DOHH-2 M3nSUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TzbGlEPTB;NT60NlI1QCEQvF2= M2fsWHNCVkeHUh?=
SW684 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE[5bmtKSzVyPUWuOlY{QDVizszN NEC2V41USU6JRWK=
CP50-MEL-B M13uV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTVwNki2PFQh|ryP NGrYdm5USU6JRWK=
UM-UC-3 MmLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXnOWlZUUN3ME21MlczOjNzIN88US=> M332WXNCVkeHUh?=
LC-2-ad Ml[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7IO5ZKSzVyPUWuO|gzPTFizszN NHXZPJBUSU6JRWK=
PC-3 NHu3ZZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXaXWxKSzVyPUWuPVE3OTVizszN MXjTRW5ITVJ?
CAN NGXJeYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHqTWM2OD13LkmyPFIh|ryP MWPTRW5ITVJ?
ESS-1 M2LSUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnUPYdtUUN3ME21Mlk4QDZ7IN88US=> NV;wRY84W0GQR1XS
ATN-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnu4TWM2OD14LkC1OVY5KM7:TR?= NF3CeG1USU6JRWK=
BxPC-3 MnnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1G1SGlEPTB;Nj6wPFIyQSEQvF2= MUPTRW5ITVJ?
KYSE-150 M{nsSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHHWIFKSzVyPU[uNVI1PzZizszN NVjDTmRwW0GQR1XS
RPMI-8866 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1O5OWlEPTB;Nj6xPVE3OyEQvF2= NVr2V4dMW0GQR1XS
SW780 NF30WnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULSbmJXUUN3ME22MlIxPDJizszN MnTJV2FPT0WU
A388 M3;pWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rOZmlEPTB;Nj6yN|EyPSEQvF2= NWfMTGNXW0GQR1XS
NCI-H1437 NWf2[XgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1q1[GlEPTB;Nj6yOFA4OyEQvF2= NUjyXopmW0GQR1XS
NCI-H1755 MoHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfuNmFKSzVyPU[uN|Y3OTJizszN MXnTRW5ITVJ?
LS-123 NW\CSXdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTQfotKSzVyPU[uOFA2OjFizszN MoPJV2FPT0WU
CaR-1 MlvMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnEbWdKSzVyPU[uOFY{PzNizszN MWjTRW5ITVJ?
RT-112 M4C2NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGP2dlhKSzVyPU[uOlA{OzhizszN MnnjV2FPT0WU
CGT MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTZwN{O2PFEh|ryP Mmm3V2FPT0WU
SW626 NWTTXYNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfETWM2OD14LkezPVQ3KM7:TR?= NWSx[YtPW0GQR1XS
AsPC-1 NYLid4dLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTZwN{S1NFch|ryP M3fIOXNCVkeHUh?=
SBC-5 NIrJbWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfWXHd1UUN3ME22Mlk4Ojl5IN88US=> NV\oTJRDW0GQR1XS
SF539 M4n1fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHNdGVKSzVyPU[uPVk{OzNizszN NVLkbngzW0GQR1XS
TI-73 MkXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPrTWM2OD15LkC2Nlg2KM7:TR?= M4TkNHNCVkeHUh?=
MHH-ES-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDMTWM2OD15LkC3O|YzKM7:TR?= Ml\EV2FPT0WU
KYSE-510 NWPQUIYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTdwMEi0N|Ih|ryP MU\TRW5ITVJ?
EW-1 NYq5[I52T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTdwM{[5PVYh|ryP NGHSOJhUSU6JRWK=
SK-OV-3 M3y5ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVL5SVB3UUN3ME23MlM6PDN{IN88US=> NGLXPY9USU6JRWK=
MC-IXC NEnx[JZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mor4TWM2OD15LkSxPVczKM7:TR?= MmPTV2FPT0WU
HSC-2 NILOO5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfVTmh3UUN3ME23MlQzPzB3IN88US=> MnfaV2FPT0WU
NCI-H2342 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTdwNUG0PUDPxE1? NYrBVo1TW0GQR1XS
NCI-H1792 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPRSpNKSzVyPUeuOVE4OTFizszN M4\LSXNCVkeHUh?=
HT-1376 NYfhVWd7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LPbWlEPTB;Nz64O|c4QCEQvF2= NEGwfWFUSU6JRWK=
EW-13 MkTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{[zdWlEPTB;Nz64PVk4PyEQvF2= NGjYdXlUSU6JRWK=
no-11 MkTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTdwOUCxO|Qh|ryP NH3XeJZUSU6JRWK=
Daoy MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fEOmlEPTB;Nz65OFMzOSEQvF2= MUDTRW5ITVJ?
COLO-800 M1LlVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jxemlEPTB;OD6wOFE3OiEQvF2= NGP5OHlUSU6JRWK=
GB-1 NEXUNXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXaTWM2OD16LkC2OVY2KM7:TR?= MmjNV2FPT0WU
SJRH30 M{DLN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknITWM2OD16LkG1PFc5KM7:TR?= NEjBRlZUSU6JRWK=
NCI-H2291 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjiTWM2OD16LkK5NVg4KM7:TR?= NFHOUYVUSU6JRWK=
J82 NGL0bJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml:3TWM2OD16LkK5OFkyKM7:TR?= NF20b4VUSU6JRWK=
NCI-H596 MljLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrxOm9sUUN3ME24MlMyPDV|IN88US=> MnPuV2FPT0WU
RERF-LC-MS MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;ScGlEPTB;OD6zOFg2PiEQvF2= MU\TRW5ITVJ?
RH-18 M2jKU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7JTWM2OD16LkO1NFQ3KM7:TR?= MkT4V2FPT0WU
SW48 M2TUcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRThwNUm0OVMh|ryP MVzTRW5ITVJ?
RD M4PD[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRThwNUmzPVEh|ryP MlfNV2FPT0WU
MS-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jKdmlEPTB;OD62NVM5PyEQvF2= NEHKRWNUSU6JRWK=
ES6 Ml35S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHWTWM2OD16LkezNVE6KM7:TR?= MW\TRW5ITVJ?
TE-12 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zzN2lEPTB;OD63O|UxPSEQvF2= M1\IWXNCVkeHUh?=
DBTRG-05MG MoO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRThwOUGyNVch|ryP NEHHWlJUSU6JRWK=
KINGS-1 MlGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnKTHdjUUN3ME24MlkzQTN6IN88US=> M2rSSHNCVkeHUh?=
HLE MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1e4d2lEPTB;OD65N|c5PSEQvF2= M{nQW3NCVkeHUh?=
MHH-NB-11 NIDnd|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXJdmd{UUN3ME25MlAyQDN7IN88US=> NYXUZlJRW0GQR1XS
U-87-MG M{\tcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjpS2NKUUN3ME25MlI1OzJzIN88US=> NYiw[mNqW0GQR1XS
MN-60 NGK0U5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTlwMkS1OFIh|ryP NVn3cG51W0GQR1XS
SAS NI\IPW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWW5OXlvUUN3ME25MlI2PThzIN88US=> M1HtV3NCVkeHUh?=
NCI-H446 MnPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4f0SWlEPTB;OT6zOlEh|ryP NUXBN24{W0GQR1XS
C-33-A NFTySYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXmyXXJDUUN3ME25MlQ{QTh6IN88US=> NFXLdYdUSU6JRWK=
RXF393 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\4W5JIUUN3ME25MlQ4ODB{IN88US=> MX;TRW5ITVJ?
CGTH-W-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHSTWM2OD17LkS5N|g1KM7:TR?= MXTTRW5ITVJ?
RCM-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HjNmlEPTB;OT62N|gxOSEQvF2= NEjlVWVUSU6JRWK=
SN12C Mo\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\aU2lEPTB;OT62OVM{QCEQvF2= MmDIV2FPT0WU
KLE NWHiSZdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\FTWM2OD17LkewNFA6KM7:TR?= MkfzV2FPT0WU
EFO-21 MmPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUD6NVZmUUN3ME25Mlc4Ozh{IN88US=> NEDofFJUSU6JRWK=
KYSE-70 NGP5VnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTlwOEiwNVEh|ryP MXzTRW5ITVJ?
D-247MG M3H1bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HQcGlEPTB;MUCuNFU3QCEQvF2= M{P0S3NCVkeHUh?=
MPP-89 MoTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnjT|ZKSzVyPUGwMlA6PDZizszN NHLJeIJUSU6JRWK=
RVH-421 M3e4bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPnTWM2OD1zMD6xOVA2KM7:TR?= M4nOOnNCVkeHUh?=
NCI-H460 NH\RZ|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknkTWM2OD1zMD6yPFA3KM7:TR?= Ml;LV2FPT0WU
NOMO-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnnTWM2OD1zMD6zOVMzKM7:TR?= NWftbmVkW0GQR1XS
DEL M3nWWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7RNoY4UUN3ME2xNE4{Pzl2IN88US=> M3r4dXNCVkeHUh?=
HT55 NFfUV3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTFyLk[yNFUh|ryP MoSxV2FPT0WU
MC116 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HTOWlEPTB;MUCuOlY2PSEQvF2= M2HjOHNCVkeHUh?=
BB30-HNC MonPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXyc3RKSzVyPUGwMlY3QSEQvF2= M4LDbXNCVkeHUh?=
DJM-1 NX7vVZRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInpVJNKSzVyPUGwMlY6PDlizszN M3XPfHNCVkeHUh?=
ZR-75-30 NGnOVYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3mzd2lEPTB;MUCuPVQ1OSEQvF2= MlXPV2FPT0WU
U-118-MG M{C2bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\zdXdKSzVyPUGwMlk5QTZizszN NH;iemJUSU6JRWK=
MSTO-211H Mkm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTFzLkC3NVYh|ryP NITzU2ZUSU6JRWK=
SW837 MmHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2[3OmlEPTB;MUGuNFk1QSEQvF2= NXPDe2tTW0GQR1XS
HuCCT1 Mn:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTDU3dZUUN3ME2xNU4yOjhzIN88US=> MneyV2FPT0WU
RCC10RGB M1;FOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTFzLkGzOUDPxE1? Mn31V2FPT0WU
NMC-G1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTFzLkG0PVMh|ryP NH\HfIJUSU6JRWK=
NCI-H650 NXL4e3hvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLjSGtDUUN3ME2xNU4{Pzl2IN88US=> NXTQU3pnW0GQR1XS
HEC-1 Mo\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTFzLkSzNlgh|ryP NFziWXFUSU6JRWK=
DU-4475 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTFzLkezPVMh|ryP M4TaVHNCVkeHUh?=
DSH1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTFzLke2NFYh|ryP MofHV2FPT0WU
HCC1569 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH73SndKSzVyPUGxMlc3PzhizszN NUTBcnN6W0GQR1XS
HCC1187 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHKTnZKSzVyPUGxMlg2QDhizszN NF3mNppUSU6JRWK=
EW-11 NYPIOVhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PCcWlEPTB;MUGuPVQ4PCEQvF2= Mn\QV2FPT0WU
LB2518-MEL MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTF{LkC1PUDPxE1? NYDTXIJHW0GQR1XS
KALS-1 M{n0UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnuPIxKSzVyPUGyMlg2PTNizszN MlztV2FPT0WU
8505C MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPh[WRKSzVyPUGyMlg5PSEQvF2= NHHX[W5USU6JRWK=
SK-N-DZ NHS4VndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\YTWM2OD1zMz6wOFU{KM7:TR?= MoTlV2FPT0WU
CHP-134 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHQd2NKSzVyPUGzMlEyPThizszN NF64OHlUSU6JRWK=
HCE-T M3nYfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHaTWM2OD1zMz6yN|Y1KM7:TR?= MYTTRW5ITVJ?
LB-831-BLC NHn4SIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\qdGlEPTB;MUOuOlI1PiEQvF2= NHP5T5hUSU6JRWK=
OVCAR-4 NHf4T3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXpOIZjUUN3ME2xN{43PTJ2IN88US=> NGrzc4ZUSU6JRWK=
SW756 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPpUFNKSzVyPUGzMlczPDZizszN Mnv0V2FPT0WU
OCUB-M M2\BXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrs[ZVKSzVyPUGzMlgyPTZizszN NVjacVhQW0GQR1XS
SW982 M1fLeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjrd5dJUUN3ME2xN{45Ojd4IN88US=> MkjsV2FPT0WU
DB M1HUW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFf5VIpKSzVyPUGzMlg{QDRizszN M2PZR3NCVkeHUh?=
H-EMC-SS NEfsToZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjWT|hmUUN3ME2xN{46OTN7IN88US=> NUPSbnFQW0GQR1XS
VMRC-RCZ M{jBV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnScoNNUUN3ME2xOE4xODF3IN88US=> MoewV2FPT0WU
CAKI-1 NXLEOZpVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnCV|VKSzVyPUG0MlAyOzJizszN MWLTRW5ITVJ?
GI-1 NV\xbIU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlyyTWM2OD1zND6wOlU5KM7:TR?= NEDmSJdUSU6JRWK=
Ca9-22 NWKxXZZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLxTWM2OD1zND62NFU1KM7:TR?= M3H1VHNCVkeHUh?=
TE-5 NEfoUVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;3TWM2OD1zND63NlA5KM7:TR?= NGrkfXNUSU6JRWK=
EFO-27 NGDvTZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnETWM2OD1zND63OlIzKM7:TR?= NXfjZYkxW0GQR1XS
CAL-72 M2fpWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHsSHB7UUN3ME2xOE44Pzh|IN88US=> NV;jZ2VQW0GQR1XS
GP5d Ml\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfr[HdKSzVyPUG1MlA1PzRizszN MUXTRW5ITVJ?
CAS-1 NUfCeIJmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInhT5RKSzVyPUG1MlA3PiEQvF2= M3P0fnNCVkeHUh?=
A2058 NGXKWm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIKzb5RKSzVyPUG1MlU3OzhizszN NYnPeXZ4W0GQR1XS
PANC-08-13 NFHWNWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTF3Lk[4OVkh|ryP NVnMXHJzW0GQR1XS
Detroit562 M1vsUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPL[FdsUUN3ME2xOU46OTN7IN88US=> NWXDTJBLW0GQR1XS
PANC-10-05 NVTVSXFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTXTWM2OD1zNj6wPFIyKM7:TR?= MYTTRW5ITVJ?
KOSC-2 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3y4fmlEPTB;MU[uNVEzPSEQvF2= NFrDeGVUSU6JRWK=
GT3TKB MkDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETjfGhKSzVyPUG2MlE6QDFizszN MoHaV2FPT0WU
KM-H2 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{[yU2lEPTB;MU[uN|Y1PiEQvF2= MW\TRW5ITVJ?
LB771-HNC NXrBTYRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{WwOmlEPTB;MU[uOFQzOiEQvF2= MmWzV2FPT0WU
SF268 M2fIWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTF4LkS1NkDPxE1? M2DPVXNCVkeHUh?=
OE19 MmfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkGyTWM2OD1zNj61NlQh|ryP M4LHTnNCVkeHUh?=
MLMA NV;RdJFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjrTWM2OD1zNj61OVcyKM7:TR?= M2LTcHNCVkeHUh?=
MDA-MB-231 M2i0Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33RU2lEPTB;MU[uO|E{PiEQvF2= NXnVfmMxW0GQR1XS
TGW NIn6[WtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LkNmlEPTB;MU[uPFExOiEQvF2= NHfhO2hUSU6JRWK=
MDA-MB-453 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTF5LkCwNFMh|ryP NFPvZ29USU6JRWK=
SNU-C2B Mn30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TDcmlEPTB;MUeuNFI{PyEQvF2= NWX1e2loW0GQR1XS
A427 MmK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;uSFFKSzVyPUG3MlI{OzRizszN NUjCfnl6W0GQR1XS
SK-MEL-2 M3Oxd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPvbZF1UUN3ME2xO{4{OjF|IN88US=> MlHTV2FPT0WU
KURAMOCHI MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTF5LkO4PVch|ryP NHrNUGJUSU6JRWK=
IST-MEL1 M2PseWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTF5LkmxPFIh|ryP NVTySG85W0GQR1XS
NCI-H1793 MoruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG[xeopKSzVyPUG4MlE2QDFizszN NIfzVlRUSU6JRWK=
HCC1395 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTF6LkW2NVEh|ryP MX7TRW5ITVJ?
NUGC-3 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTF6Lk[1PFQh|ryP MYXTRW5ITVJ?
BB65-RCC M4fLRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2X3OGlEPTB;MUiuOlY6KM7:TR?= NFrZR2hUSU6JRWK=
RMG-I MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTF6LkezPFIh|ryP MVfTRW5ITVJ?
LS-513 M4rsWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXrTWM2OD1zOD65NlI5KM7:TR?= NX7jdpA6W0GQR1XS
MFM-223 M{jX[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfhW3E4UUN3ME2xPU4xPzF4IN88US=> M1PFRnNCVkeHUh?=
NCI-H727 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2K3NGlEPTB;MUmuN|I6PSEQvF2= M4fBTnNCVkeHUh?=
KP-4 M2XYNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7tS4hKSzVyPUG5Mlg2OzFizszN MnLSV2FPT0WU
NB13 M1HGV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTF7Lki4N|kh|ryP NVPtfplyW0GQR1XS
UACC-893 M2i2Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;KTWM2OD1zOT65O|U4KM7:TR?= MUfTRW5ITVJ?
HT-1197 NGfpdGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LKfGlEPTB;MkCuNlk2QCEQvF2= NFjPZnRUSU6JRWK=
NCI-H2029 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTJyLkOyOlYh|ryP M4rnUHNCVkeHUh?=
GI-ME-N MnvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DtNmlEPTB;MkCuN|M4OyEQvF2= MnP6V2FPT0WU
OVCAR-3 M1S1Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13wV2lEPTB;MkCuOVgzOiEQvF2= MVXTRW5ITVJ?
HD-MY-Z MonTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTJzLkO2PVYh|ryP MonLV2FPT0WU
NTERA-S-cl-D1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7vW3BKSzVyPUKxMlY4OjJizszN NYLOWoZKW0GQR1XS
SCH MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PK[mlEPTB;MkKuOFk3KM7:TR?= MlzTV2FPT0WU
KARPAS-299 M3vKOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\Ec2lEPTB;MkOuN|g5PyEQvF2= NFnJTWhUSU6JRWK=
NCI-H1650 NV\Qc20yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTJ|LkmyOFEh|ryP MUXTRW5ITVJ?
ACHN NV;XOnNwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTJ2LkS2OVYh|ryP M3HWdnNCVkeHUh?=
M059J NIXkOFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1H3bWlEPTB;MkSuOVY{PCEQvF2= Mm\2V2FPT0WU
AM-38 MlPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTJ3LkS4NUDPxE1? NWPvc|dWW0GQR1XS
KG-1 NYXtcXhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnu3TWM2OD1{NT61OFk1KM7:TR?= M3TEVnNCVkeHUh?=
COLO-824 MkjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrB[ZBnUUN3ME2yOU42PTl7IN88US=> NYS5d2JxW0GQR1XS
NCI-H1155 NUDS[IRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml20TWM2OD1{NT61PFQ4KM7:TR?= MlnKV2FPT0WU
NCI-H441 NUi3ZVZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTJ3Lke0OlUh|ryP NUjLSZN[W0GQR1XS
J-RT3-T3-5 M3j3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTJ4LkOwNlch|ryP MXnTRW5ITVJ?
JEG-3 NIHwZpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTJ4Lk[4NFUh|ryP NYjmWW1sW0GQR1XS
RKO NVv0O2VzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrDZWNKSzVyPUK2Mlc3OzJizszN NW\YcWZjW0GQR1XS
CAL-85-1 M4\vN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXDOHRqUUN3ME2yO{4zOTF6IN88US=> MWnTRW5ITVJ?
CAL-120 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILjOmhKSzVyPUK3MlY6OTRizszN NV3FS4VGW0GQR1XS
NCI-H2452 NGPBT|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTJ5Lke3NVYh|ryP Ml25V2FPT0WU
NCI-H1395 NVjNV3N6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDSTWM2OD1{Nz63PFM{KM7:TR?= MmnJV2FPT0WU
KYSE-450 MmqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEK4eFlKSzVyPUK3Mlk5PjJizszN MV3TRW5ITVJ?
S-117 NETMU3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTJ7LkO4OVch|ryP MYnTRW5ITVJ?
SW13 M1LJVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTJ7Lki1NVkh|ryP MXXTRW5ITVJ?
ES3 NX3C[GNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTNyLkO3N|Mh|ryP NU\6cpJwW0GQR1XS
HCT-116 M{P0RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3kTWM2OD1|MD61OVU1KM7:TR?= NYT5clBjW0GQR1XS
NCI-H1693 Mn;XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXoTZg2UUN3ME2zNE42QTR{IN88US=> NFP6TWZUSU6JRWK=
VM-CUB-1 NGjLVHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIizNIpKSzVyPUOwMlY1OTNizszN MXnTRW5ITVJ?
NCI-H2170 MkTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTNzLkW3PFQh|ryP NVLVVo1ZW0GQR1XS
ALL-PO M4DYO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvxXGpzUUN3ME2zNU45PDJ6IN88US=> NULNeVQ{W0GQR1XS
NCI-H661 M{noWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjhOldKSzVyPUOyMlA3OjNizszN NWf2RWRbW0GQR1XS
NCI-H2347 MnfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXUeZFKSzVyPUOyMlQ5OzdizszN NHLrW|dUSU6JRWK=
FTC-133 Mn2wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXwfYVwUUN3ME2zNk44ODZizszN NV7BbJJzW0GQR1XS
COLO-829 NXz0XFlkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTN|LkO0Olch|ryP NWnYfottW0GQR1XS
GOTO NFnRUZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzuSmV4UUN3ME2zN{42OjV6IN88US=> NFLXbGxUSU6JRWK=
YAPC NWTxTJFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTN|LkixOVkh|ryP MYPTRW5ITVJ?
LCLC-103H MnHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTN2LkG2NlQh|ryP NIfqcpVUSU6JRWK=
SiHa MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTN2LkO4NVch|ryP NITvZ4ZUSU6JRWK=
LK-2 NI\LRphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTN2LkW3NFgh|ryP MWHTRW5ITVJ?
KP-N-YS MmL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTN2LkeyNFIh|ryP NEfheYVUSU6JRWK=
NCI-SNU-1 NULOZXJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml2yTWM2OD1|NT6xO|kh|ryP M1XyR3NCVkeHUh?=
KNS-81-FD Mk[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTN3Lk[2N{DPxE1? MX3TRW5ITVJ?
SCC-9 MlzBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTN4LkexOFYh|ryP MYjTRW5ITVJ?
SH-4 NV75NXFST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVz5b3VmUUN3ME2zOk44OyEQvF2= M131fHNCVkeHUh?=
HCC-1954 Mm\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2mwZWlEPTB;M{euNlczQSEQvF2= NXy3WolPW0GQR1XS
BALL-1 M2H4WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPBTWM2OD1|Nz61N|E3KM7:TR?= NGL5Sm1USU6JRWK=
BE-13 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fIO2lEPTB;M{euO|AyQCEQvF2= MYTTRW5ITVJ?
COLO-678 NHP5UpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrzTVZKSzVyPUO3Mlk1OzdizszN MVPTRW5ITVJ?
SK-MEL-3 M{jmU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIntXXNKSzVyPUO4MlI{QTdizszN Mne0V2FPT0WU
OAW-28 M3fyUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIK5UYxKSzVyPUO4MlY{QSEQvF2= NXvIXpl1W0GQR1XS
CAMA-1 NIjkfJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\nZWlEPTB;M{iuPVY6OSEQvF2= NX;kUHF5W0GQR1XS
C2BBe1 NV7Nc5ZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fNNWlEPTB;M{muPFE5KM7:TR?= NYXRVlhwW0GQR1XS
A3-KAW NXP0W4FvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTRyLkO2OlEh|ryP NIr4fJFUSU6JRWK=
SK-MEL-24 MoPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jSNGlEPTB;NECuOVk{OSEQvF2= NECxfFRUSU6JRWK=
KYSE-140 MlzCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTRyLkexOlUh|ryP MmTVV2FPT0WU
MOLT-16 NXHWbZVXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTRzLkG1N|Yh|ryP NUHLR|M6W0GQR1XS
CFPAC-1 Ml3VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXPT|ZKSzVyPUSyMlUzOTFizszN NX;TS5pFW0GQR1XS
NB14 NXXkdnp1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\ZWoZKSzVyPUSyMlcxOjdizszN MUTTRW5ITVJ?
COLO-792 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmexTWM2OD12Mj64PVYyKM7:TR?= NInzb3FUSU6JRWK=
RH-1 NHH5fpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjBZ|NtUUN3ME20N{41QDN4IN88US=> NUT2eHJsW0GQR1XS
NCI-H522 M3vudWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTR2LkO1Olgh|ryP M2XabHNCVkeHUh?=
Ca-Ski MnHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2mxR2lEPTB;NESuPFEyPCEQvF2= MXjTRW5ITVJ?
KGN NFXaUJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTR6LkOwOlMh|ryP M2jkSnNCVkeHUh?=
UACC-62 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTR6LkSwO|Ih|ryP MYPTRW5ITVJ?
NCI-H358 MmjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfxXXBKSzVyPUS5MlMxOThizszN M13ucXNCVkeHUh?=
LS-411N NGX6VJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTR7LkOxNVgh|ryP MWfTRW5ITVJ?
IST-MES1 NWfzTHNFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\xOVNKSzVyPUS5MlU3OjVizszN NXL0NFFrW0GQR1XS

多くの細胞株試験データを見る場合、クリックしてください

体内試験 Administration of GDC-0941 at 75 mg/kg/day displays significant inhibitory effect against established human U87MG glioblastoma xenografts in female NCr athymic mice, with tumor growth inhibition of 83%. [1] Oral administration of GDC-0941 at 150 mg/kg/day inhibits the growth of HER2-amplified, trastuzumab-resistant MDA-MB-361.1 xenografts in mice, and significantly delays the tumor progression, in association with potent induced apoptosis in tumors. [2] GDC-0941 (75 mg/kg/day) treatment for 2 weeks induces ~40% reduction in tumor volume of spontaneous B-cell follicular lymphomas developed in PTEN+/-LKB1+/hypo mice, accompanied by ablation of phosphorylation of Akt, S6K and SGK (serum and glucocorticoid protein kinase) protein kinases. [4]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[1]
+ 展開

Scintillation proximity assay:

Recombinant human PI3Kα, PI3Kβ, and PI3Kδ are coexpressed in a Sf9 baculovirus system with the p85α regulatory subunit and purified as GST-fusion proteins using affinity chromatography on glutathione-sepharose. Recombinant human PI3Kγ is expressed as monomeric GST-fusions and purified similarly. GDC-0941 is dissolved in DMSO and added to 20 mM Tris-HCl (pH 7.5) containing 200 μg yttrium silicate (Ysi) polylysine SPA beads, 4 mM MgCl2, 1 mM dithiothreitol (DTT), 1 μM ATP, 0.125 μCi [γ-33P]-ATP, and 4% (v/v) DMSO in a total volume of 50 μL. The recombinant GST-fusion of PI3Kα (5 ng), PI3Kβ (5 ng), PI3Kδ (5 ng), or PI3Kγ (5 ng) is added to the assay mixture to initiate the kinase reaction. After incubation for 1 hour at room temperature, the kinase reaction is terminated with 150 μL PBS. The mixture is then centrifuged for 2 minutes at 2000 rpm and read using a Wallac Microbeta counter. The reported IC50 values are calculated using a sigmoidal, dose-response curve fit in MDL Assay Explorer.
細胞試験: [2]
+ 展開
  • 細胞株: SKBR-3, BT474-M1, AU-565, HCC-1419, ZR75-30, KPL-4, JIMT-1, BT474-EEI, HCC-1954, MCF-7, CALU-3, SKOV-3, and MKN-7 cells
  • 濃度: Dissolved in DMSO, final concentrations ~10 μM
  • 反応時間: 48 and 72 hours
  • 実験の流れ: Cells are exposed to various concentrations of GDC-0941 for 48, and 72 hours. Proliferation/viability of cells is detected by using the CellTiter-Glo Luminescent Cell Viability Assay. The pAkt (Ser473), cleaved caspase-3, and cleaved PARP are analyzed by western blot. The Caspase-Glo 3/7 assay and the Cell Death Detection ELISAplus assay are used to detect caspase 3/7 activity, and apoptosis, respectively.
    (参考用のみ)
動物試験:[2]
+ 展開
  • 動物モデル: NCR nude mice implanted with MDA-MB-361.1 cells, and SCID, C.B-17/IcrHsd-Prkdcscid mice implanted subcutaneously with BT474-M1 cells
  • 製剤: Dissolved in 10% DMSO, 5% Tween 20, 85% water
  • 投薬量: ~150 mg/kg/day
  • 投与方法: Oral gavage
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 44 mg/mL (85.66 mM)
Water slightly soluble or insoluble
Ethanol slightly soluble or insoluble
体内 順序で溶剤を入れること:
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
5mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 513.64
化学式

C23H27N7O3S2

CAS No. 957054-30-7
保管
in solvent
別名 RG7321

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00999128 Completed Healthy Volunteers Genentech, Inc. October 26, 2009 Phase 1
NCT02092831 Completed Healthy Volunteer Genentech, Inc. April 2014 Phase 1
NCT01740336 Active, not recruiting Breast Cancer Genentech, Inc. February 2013 Phase 2
NCT01493843 Completed Non-Squamous Non-Small Cell Lung Cancer Genentech, Inc. January 2012 Phase 2
NCT01474668 Completed Healthy Volunteer Genentech, Inc. October 2011 Phase 1
NCT01437566 Completed Breast Cancer Genentech, Inc. October 2011 Phase 2

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

PI3K信号経路図

PI3K Inhibitors with Unique Features

相関PI3K製品

Tags: Pictilisib (GDC-0941)を買う | Pictilisib (GDC-0941) ic50 | Pictilisib (GDC-0941)供給者 | Pictilisib (GDC-0941)を購入する | Pictilisib (GDC-0941)費用 | Pictilisib (GDC-0941)生産者 | オーダーPictilisib (GDC-0941) | Pictilisib (GDC-0941)化学構造 | Pictilisib (GDC-0941)分子量 | Pictilisib (GDC-0941)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID